• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Merck Animal Health Selects Salesforce's Agentforce Life Sciences for Customer Engagement to Transform Animal Care and Enhance Support Experiences for Employees

    5/6/26 9:00:00 AM ET
    $CRM
    $MRK
    Computer Software: Prepackaged Software
    Technology
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CRM alert in real time by email

    Salesforce (NYSE:CRM), the world's #1 AI CRM, and Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc. (NYSE:MRK), today announced that Merck Animal Health has selected Agentforce Life Sciences for Customer Engagement to create a unified, 360-degree view and support experience for veterinarians, pet owners, and production animal farmers across all channels.

    Leveraging Agentforce 360, Merck Animal Health aims to improve access to its medicines and devices and drive efficiencies with:

    • Unified customer views, using the Agentforce 360 Platform as its secure, single source of truth with Data 360 to unify information sources like production monitoring devices, pet microchips, and automatic feeders with prescription history and preferences.
    • Always-on self-service, leveraging a centralized, omni-channel contact center, including Experience Cloud to create centralized landing pages and a seamless digital ecommerce experience for its wellness services and products.
    • Hyperpersonalize B2B and B2C programs with tailored Agentforce Marketing journeys and campaigns, connected across sales and marketing, including subscription and warranty management to boost vet and animal owner loyalty.
    • Intelligent sales powered by Agentforce Life Sciences, creating a conversational user experience with ready-to-use, industry-specific workflows and actions for account tracking, incentive compensation, and up- and cross-sell opportunities.

    By consolidating monitoring technology and biopharma systems across business units onto a single platform, Merck Animal Health will be able to better serve its customers, reduce waste, and lower its cost to serve while increasing acquisition and retention and achieving its mission through "The Science of Healthier Animals®."

    "At Merck Animal Health, we support the strong bond between people and their pets and help protect international public health, ensure food safety, and increase protein supply. Using Salesforce's Agentforce Life Sciences as our ‘OneCRM,' we will reimagine the way we engage with our veterinarians, pet owners, production animal farmers, and the animals under their care." — Juanjo Francesch, VP, Animal Health IT, Merck Animal Health

    "One of the most critical challenges for animal health is often a fragmented view of care, making it difficult for veterinarians to deliver seamless support. Our partnership with Merck Animal Health and the deployment of Agentforce Life Sciences gives them a unified, intelligent platform to finally break down those data silos. This is more than just a system upgrade. We're fundamentally reimagining how veterinarians deliver care, ensuring the best possible health outcomes for pets and livestock around the world." — Tara Helm, Life Sciences Solutions Strategy Leader, Salesforce

    About Merck Animal Health

    Merck Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA, is a global animal health business committed to The Science of Healthier Animals®. For more than 130 years, we have pioneered groundbreaking science. Today, we are driven by continuous innovation to develop breakthrough medicines, vaccines and technology. Rooted in direct experience on the farm and in the clinic, we work hand in hand with our customers every step of the way. Our singular focus is to empower those who care for animals, helping them manage their vital responsibility with confidence. Because when it comes to animal health, no one sees it like we do. For more information, visit http://www.merck-animal-health.com/ and connect with us on LinkedIn, Facebook, X (formerly Twitter) and Instagram.

    About Salesforce

    Salesforce helps organizations of any size become Agentic Enterprises — integrating humans, agents, apps, and data on a trusted, unified platform to unlock unprecedented growth and innovation. Visit salesforce.com for more information.

    Any unreleased services or features referenced here are not currently available and may not be delivered on time or at all. Customers should make their purchase decisions based upon features that are currently available.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20260506784894/en/

    Ned Ehrbar

    Merck

    Global Media Relations

    646-593-1669

    ned.ehrbar@merck.com

    Maha Neouchy

    Salesforce

    Public Relations

    408-568-8442

    pr@salesforce.com

    Get the next $CRM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CRM
    $MRK

    CompanyDatePrice TargetRatingAnalyst
    Salesforce Inc.
    $CRM
    5/18/2026$160.00Underperform
    BofA Securities
    Merck & Company Inc.
    $MRK
    5/6/2026$125.00Neutral
    Citigroup
    Salesforce Inc.
    $CRM
    2/26/2026$235.00 → $225.00Outperform
    BMO Capital Markets
    Merck & Company Inc.
    $MRK
    2/25/2026$142.00Outperform
    RBC Capital Mkts
    Merck & Company Inc.
    $MRK
    2/20/2026$140.00Overweight
    Barclays
    Salesforce Inc.
    $CRM
    2/20/2026$275.00 → $235.00Outperform
    BMO Capital Markets
    Merck & Company Inc.
    $MRK
    2/13/2026$150.00Hold → Buy
    Deutsche Bank
    Salesforce Inc.
    $CRM
    1/12/2026$330.00Buy
    Goldman
    More analyst ratings

    $CRM
    $MRK
    SEC Filings

    View All

    Salesforce Inc. filed SEC Form 8-K: Leadership Update

    8-K - Salesforce, Inc. (0001108524) (Filer)

    6/2/26 4:15:12 PM ET
    $CRM
    Computer Software: Prepackaged Software
    Technology

    SEC Form S-8 filed by Salesforce Inc.

    S-8 - Salesforce, Inc. (0001108524) (Filer)

    6/1/26 5:10:34 PM ET
    $CRM
    Computer Software: Prepackaged Software
    Technology

    Salesforce Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Leadership Update, Financial Statements and Exhibits

    8-K - Salesforce, Inc. (0001108524) (Filer)

    6/1/26 4:43:09 PM ET
    $CRM
    Computer Software: Prepackaged Software
    Technology

    $CRM
    $MRK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BofA Securities resumed coverage on Salesforce with a new price target

    BofA Securities resumed coverage of Salesforce with a rating of Underperform and set a new price target of $160.00

    5/18/26 8:36:39 AM ET
    $CRM
    Computer Software: Prepackaged Software
    Technology

    Citigroup resumed coverage on Merck with a new price target

    Citigroup resumed coverage of Merck with a rating of Neutral and set a new price target of $125.00

    5/6/26 7:35:08 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BMO Capital Markets reiterated coverage on Salesforce with a new price target

    BMO Capital Markets reiterated coverage of Salesforce with a rating of Outperform and set a new price target of $225.00 from $235.00 previously

    2/26/26 6:51:04 AM ET
    $CRM
    Computer Software: Prepackaged Software
    Technology

    $CRM
    $MRK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Warden Kathy J

    4 - Merck & Co., Inc. (0000310158) (Issuer)

    6/2/26 4:14:55 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Karsanbhai Surendralal Lanca

    4 - Merck & Co., Inc. (0000310158) (Issuer)

    6/2/26 3:31:57 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Coe Mary Ellen

    4 - Merck & Co., Inc. (0000310158) (Issuer)

    6/2/26 2:26:39 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRM
    $MRK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ModelFront Announces Outcome-Based Pricing

    Customers pay only for saved words, making translation AI ROI direct and predictable. ModelFront today announced outcome-based pricing, a win-win structure that aligns the cost of AI with the value it creates, to provide a more secure return on investment. ModelFront is AI to check and fix AI translations. It automatically verifies segments that humans would verify unedited, and triggers human intervention for those that need it. Enterprise translation buyers use ModelFront to automate and scale while keeping human quality. Under the outcome-based pricing structure, customers only pay for saved words — words in segments that were verified by AI. There is no AI cost for the bits of con

    6/3/26 12:00:00 PM ET
    $ADBE
    $CG
    $CRM
    Computer Software: Prepackaged Software
    Technology
    Investment Managers
    Finance

    Apotex launches sitagliptin tablets and sitagliptin and metformin hydrochloride tablets, eligible for 180-day shared exclusivity

    WESTON, Fla., June 3, 2026 /CNW/ - Apotex Corp. ("Apotex") today announced the U.S. launch of sitagliptin tablets and sitagliptin and metformin hydrochloride tablets, both of which are eligible for 180‑day shared exclusivity. These launches expand Apotex's portfolio of treatment options for adults living with type 2 diabetes mellitus.  Type 2 diabetes affects millions of adults in the United States, and treatment often requires long-term, reliable access to prescribed therapies. Sitagliptin tablets are AB rated (per FDA's Approved Drug Products with Therapeutic Equivalence Evaluations) to JANUVIA® (Merck) and are indicated as a

    6/3/26 9:00:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Merck to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

    Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today that Robert M. Davis, chairman and chief executive officer, and Dr. Dean Y. Li, executive vice president and president, Merck Research Laboratories, are scheduled to participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026, at 11:20 a.m. ET. Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation at this weblink. About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to s

    6/2/26 6:45:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRM
    $MRK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kirk David Blair bought $500,722 worth of shares (1,936 units at $258.64), increasing direct ownership by 22% to 10,677 units (SEC Form 4)

    4 - Salesforce, Inc. (0001108524) (Issuer)

    12/18/25 5:10:12 PM ET
    $CRM
    Computer Software: Prepackaged Software
    Technology

    Director Morfit G Mason bought $25,015,680 worth of shares (96,000 units at $260.58) (SEC Form 4)

    4 - Salesforce, Inc. (0001108524) (Issuer)

    12/8/25 9:30:14 AM ET
    $CRM
    Computer Software: Prepackaged Software
    Technology

    Director Kirk David Blair bought $865,827 worth of shares (3,400 units at $254.66), gifted 4,278 shares and received a gift of 4,278 shares, increasing direct ownership by 1,811% to 8,102 units (SEC Form 4)

    4 - Salesforce, Inc. (0001108524) (Issuer)

    9/10/25 7:45:16 PM ET
    $CRM
    Computer Software: Prepackaged Software
    Technology

    $CRM
    $MRK
    Leadership Updates

    Live Leadership Updates

    View All

    Merck's Playing with Heart Program Teams Up With Professional Baseball Clubs and Baseball Legends to Help Raise Awareness About LDL-C, Called "Bad" Cholesterol, and How It May Impact the Risk of Heart Attack or Stroke

    The Yankees, Red Sox, Phillies, Braves, Astros, Cardinals, Giants, Padres, and Angels are joining Merck to help educate fans about high bad cholesterol and how it may increase the risk of heart attack or stroke Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced a collaboration with nine professional baseball teams and former professional baseball players to launch the Playing with Heart educational program to help educate adults about the importance of knowing their low-density lipoprotein cholesterol (LDL-C), called "bad" cholesterol, number and the potential increased risk of heart attack or stroke. Playing with Heart connects Merck's commitment to

    4/28/26 6:45:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Merck Evolves Human Health Operating Structure to Support Portfolio Execution

    Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today highlighted steps to evolve the structure of its Human Health organization to ensure strong commercial execution of launches across diverse therapeutic areas, positioning the company for continued commercial success. As part of this evolution, Merck is organizing its Human Health business into an Oncology Business Unit and a Specialty, Pharma & Infectious Diseases Business Unit. This structure will enable Merck to sustain long-term leadership in oncology, while maintaining a sharp focus in support of a growing number of launches across an increasingly broad and diverse portfolio. In support of the new Human He

    2/23/26 6:45:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Merck to Acquire Cidara Therapeutics, Inc., Diversifying Its Portfolio to Include Late-Phase Antiviral Agent

    CD388 is an investigational long-acting, strain-agnostic antiviral agent currently in Phase 3, designed to prevent influenza infection in individuals at higher risk of influenza complications Acquisition aligns with Merck's science-led business development strategy, diversifying and expanding the company's pipeline Merck (NYSE:MRK), known as MSD outside of the United States and Canada, and Cidara Therapeutics, Inc. (NASDAQ:CDTX) ("Cidara"), a biotechnology company developing drug-Fc conjugate (DFC) therapeutics, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Cidara for $221.50 per share in cash, for a tot

    11/14/25 6:45:00 AM ET
    $CDTX
    $MRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $CRM
    $MRK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Salesforce Inc.

    SC 13G/A - Salesforce, Inc. (0001108524) (Subject)

    11/14/24 1:22:34 PM ET
    $CRM
    Computer Software: Prepackaged Software
    Technology

    SEC Form SC 13G filed by Salesforce Inc.

    SC 13G - Salesforce, Inc. (0001108524) (Subject)

    10/16/24 12:53:21 PM ET
    $CRM
    Computer Software: Prepackaged Software
    Technology

    SEC Form SC 13G/A filed by Salesforce Inc. (Amendment)

    SC 13G/A - Salesforce, Inc. (0001108524) (Subject)

    2/13/24 5:13:53 PM ET
    $CRM
    Computer Software: Prepackaged Software
    Technology

    $CRM
    $MRK
    Financials

    Live finance-specific insights

    View All

    Salesforce Announces Quarterly Dividend

    Salesforce (NYSE:CRM), the #1 Agentic CRM, today announced that its board of directors declared a quarterly cash dividend of $0.44 per share. The dividend is payable July 2, 2026 to shareholders of record on June 11, 2026. About Salesforce Salesforce helps organizations of any size become agentic enterprises — integrating humans, agents, apps, and data on a trusted, unified platform to unlock unprecedented growth and innovation. Visit www.salesforce.com for more information. View source version on businesswire.com: https://www.businesswire.com/news/home/20260528198039/en/ Valmik Desai Salesforce Investor Relations investor@salesforce.com Kalynn Sharum Salesforce Public Relations pr@s

    5/28/26 7:31:00 PM ET
    $CRM
    Computer Software: Prepackaged Software
    Technology

    Merck Announces Third-Quarter 2026 Dividend

    Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.85 per share of the company's common stock for the third quarter of 2026. Payment will be made on July 8, 2026, to shareholders of record at the close of business on June 15, 2026. About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intens

    5/26/26 1:28:00 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Salesforce Announces Date of First Quarter Fiscal 2027 Earnings Release and Webcast

    Results to be released on May 27, 2026, after market close Salesforce (NYSE:CRM), the world's #1 AI CRM, today announced that its first quarter fiscal 2027 results will be released on Wednesday, May 27, 2026, after the close of the market. The company will host a live broadcast at 2:00 p.m. (PT) / 5:00 p.m. (ET) to discuss its financial results with the investment community. The live broadcast and replay of the event will be available on the Salesforce Investor Relations website at www.salesforce.com/investor. About Salesforce Salesforce helps organizations of any size become agentic enterprises — integrating humans, agents, apps, and data on a trusted, unified platform to unlock unpr

    5/6/26 4:30:00 PM ET
    $CRM
    Computer Software: Prepackaged Software
    Technology